In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Growth

Set Alert for Growth

VC Playbook: Finding Early-Stage Financing When Money Is Scarce

Early-stage companies need to be more flexible on the financing terms they are willing to accept and in finding ways to gather evidence to support the impact of their products or services.

VC Playbook Business Strategies

Snapshot: February Highlights

A selection of articles you may have missed from February 2023, during which In Vivo focused on the art of dealmaking and its impacts on the life sciences as a whole.

Commercial Deals

Deals Shaping The Medical Industry, January 2023

In Vivo's deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in January 2023. Data provided by Biomedtracker.

Commercial Deals

Deals Of The Year 2022 Winners Revealed

For In Vivo's 15th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.

Deals Financing

A Candidate’s Market: How Can Medtechs Attract And Retain Staff They Need In 2023?

Attracting and retaining talent is harder than ever for medtech companies. Changing lifestyles, the expectation that loyalty will be less rewarding than job hopping, and various other economic and social factors have all helped contribute to chronic staffing shortages throughout medtech.

Strategy Leadership

India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023

India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. In Vivo's sister publication Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023.

India Commercial

2023 Will Be A Year Of Partnerships And Acquisitions For Astellas

Astellas’ Mike Luther sees 2023 as a year of growing assets and creating partnerships. The global head of search and evaluation business development told In Vivo about the company's focus on gene and cell therapy and what he thinks makes for a successful business deal.

Commercial Strategies Business Strategies

Looking Beyond The Deal In England

Agreement of deals that promise better value for money and enhanced patient access to new treatments has become routine in England, but are they delivering?

Deals Commercial

Deals In 2023: Partnerships And Modest M&A

Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.

Growth Deals

Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals

The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.

M & A Deals

Slew Of Challenges Calls For Revised Biopharma Playbook

While not immune to the impact of a storm of macroeconomic pressures, pharma companies have pulled through before, and they’ll do it again. However, this time around, the economic, geopolitical and internal cost and revenue pressures are unique and weathering the near-term turbulence will call for smart investment strategies that not only focus on quality assets, but that update companies to take advantage of new digital opportunities.

Business Strategies Growth

GE HealthCare Stretches To The Next Level

GE HealthCare added a new chapter to the 130-year history of GE Corp when it spun off from the group on 3 January. CEO Peter Arduini laid out his plans for the standalone medtech giant at the company’s recent Investor Day 2022.

Growth Medical Device
See All
UsernamePublicRestriction

Register